Palvella Therapeutics Quarterly Balance Sheet
NASDAQ: PVLAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Palvella Therapeutics financial position
As of Jun 30, 2026, Palvella Therapeutics reported total assets of $253.5 million, up 243.8% from a year earlier against total liabilities of $36.6 million. Shareholders' equity stood at $216.9 million, or 85.5% of assets. The company held $187.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 21.18, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Palvella Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 187.80M | 206.39M | 57.98M | 63.57M | 70.43M | 75.63M | 83.60M | 19.36M | 19.73M | 19.08M | 7.35M | 32.89M |
| Short-Term Investments | 62.78M | 55.46M | 0 | — | — | — | — | 0 | 0 | 0 | 8.97M | 11.92M |
| Receivables | — | — | 0 | 0 | 0 | 0 | 358.00K | 373.00K | 1.49M | 1.84M | 0 | 1.04M |
| Total Current Assets | 253.03M | 263.23M | 58.99M | 66.94M | 73.75M | 79.44M | 88.23M | — | — | — | 7.55M | 59.09M |
| Property, Plant & Equipment | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Total Assets | 253.51M | 263.76M | 59.56M | 66.94M | 73.75M | 79.44M | 88.23M | 20.52M | 25.05M | 29.50M | 7.55M | 59.38M |
| Accounts Payable | 6.79M | 5.44M | 4.59M | 3.48M | 4.56M | 4.44M | 4.59M | 801.00K | 969.00K | 1.52M | 936.00K | 2.82M |
| Total Current Liabilities | 11.95M | 9.12M | 11.34M | 10.31M | 9.62M | 8.98M | 12.04M | 4.25M | 6.35M | 7.53M | 2.36M | 28.87M |
| Total Liabilities | 36.64M | 31.45M | 31.58M | 28.25M | 25.97M | 23.86M | 25.63M | 107.93M | 105.88M | 106.37M | 11.43M | 28.87M |
| Shareholders' Equity | 216.87M | 232.31M | 27.98M | 38.68M | 47.78M | 55.58M | 62.61M | -87.40M | -80.83M | -76.87M | -74.48M | 30.51M |
| Retained Earnings | -173.09M | -151.22M | -135.45M | -122.74M | -111.39M | -101.92M | -93.73M | -326.33M | -323.45M | -319.86M | -76.30M | -310.38M |
| Net Cash (Debt) | 250.58M | 261.85M | 57.98M | 63.57M | 70.43M | 75.63M | 83.60M | 19.36M | 19.73M | 19.08M | 16.32M | 44.81M |
| Shares Outstanding | 14.40M | 14.31M | 12.38M | 11.09M | 11.06M | 11.02M | 11.01M | 1.32M | 1.32M | 1.24M | 1.77M | — |
This table shows 12 quarterly periods of Palvella Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow PVLA's reporting calendar. What is a balance sheet?